Figure 7.
Platelet function is improved by ex vivo addition of Haemate P. Comparison of the volume of thrombi formed in the presence or absence of Haemate P added ex vivo to blood from healthy donors (n = 6), Btk inhibitor naïve CLL patients (n = 5), or patients receiving ibrutinib (n = 6) or acalabrutinib (n = 8, as described in Figure 7). Two-way ANOVA with repeated measures and Sidak multiple comparisons test.